内皮功能障碍生物标志物与CKD发病:REGARDS队列研究
REGARDS前瞻性队列纳入3300例基线无CKD及白蛋白尿的成人,基线检测ICAM-1、VCAM-1、FVIII和E-selectin,约9.4年后随访肾脏结局。校正后四种标志物每升高1个标准差均与CKD发病正相关,FVIII还与白蛋白尿发病相关。
要点
- ICAM-1、VCAM-1、FVIII、E-selectin升高均与CKD发病独立相关
- 四种标志物升高同样与eGFR下降≥30%风险相关
- 仅FVIII升高与白蛋白尿发病正相关
核心结论
- ICAM-1、VCAM-1、FVIII和E-selectin浓度较高与CKD发病及eGFR下降≥30%相关,FVIII还与白蛋白尿发病相关。
研究设计与样本
- REGARDS为前瞻性队列,纳入30239名年龄≥45岁的黑人或白人成人。
- 在3300名基线无CKD及白蛋白尿且参加第二次访视(9.4年后)的参与者中检测基线生物标志物。
- 采用序贯校正逻辑回归模型评估生物标志物与肾脏结局的关联。
主要发现
- 参与者中位年龄62岁,女性占49%,黑人占46%。
- 228例(6.9%)发生CKD,613例(18.9%)eGFR下降≥30%,356例(11.4%)发生白蛋白尿。
- CKD发病校正OR:ICAM-1每1 SD为1.12(95%CI 1.02-1.22),VCAM-1为1.10(95%CI 1.01-1.20),FVIII为1.15(95%CI 1.06-1.24),E-selectin为1.10(95%CI 1.01-1.20)。
- eGFR下降≥30%的结果与CKD发病相似;白蛋白尿仅与FVIII升高正相关。
关键数值与推荐
- CKD定义为eGFR<60 ml/min per 1.73 m2且较基线下降≥40%,或新发终末期肾病。
- eGFR下降≥30%为独立肾脏结局。
- 白蛋白尿定义为尿白蛋白肌酐比(ACR)≥30 mg/g。
临床怎么用
- 内皮功能障碍生物标志物或有助于识别CKD高风险人群,但当前数据尚不支持用于常规风险分层。
- FVIII可能同时提示CKD与白蛋白尿风险,宜结合eGFR和ACR综合评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic kidney disease (CKD) is only partly caused by traditional risk factors. Endothelial dysfunction is common in CKD and may contribute to CKD incidence. We studied the association of circulating biomarkers reflecting endothelial dysfunction with incident CKD. METHODS: The Reasons for Geographical and Racial Differences in Stroke (REGARDS) study is a prospective cohort of 30,239 Black or White adults aged ≥45 years. Baseline levels of intercellular cellular adhesion molecule 1 (ICAM-1), vascular cellular adhesion molecule 1 (VCAM-1), factor VIII (FVIII), and E-selectin were measured in 3300 participants without baseline CKD or albuminuria who attended a second visit 9.4 years later. Kidney outcomes were incident CKD (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m2 and ≥40% decline or onset of new end-stage kidney disease), incident ≥30% eGFR decline, and incident albuminuria (albumin-to-creatinine ratio [ACR] ≥30 mg/g). Sequentially adjusted logistic regression models assessed the association of biomarkers with kidney outcomes. RESULTS: Median age of participants was 62 years, 49% were women, and 46% identified as Black. Of the participants, 228 (6.9%) developed CKD, 613 (18.9%) experienced ≥30% decline in eGFR, and 356 (11.4%) developed albuminuria. The adjusted odds ratios (ORs) for incident CKD per 1 SD increment biomarker was 1.12 for ICAM-1 (95% confidence interval [CI]: 1.02-1.22), 1.10 for VCAM-1 (95% CI: 1.01-1.20), 1.15 for FVIII (95% CI: 1.06-1.24), and 1.10 for E-selectin (95% CI: 1.01-1.20). Results were similar for incident ≥30% eGFR decline but not albuminuria, where only higher FVIII was positively associated. CONCLUSION: Higher concentration of ICAM-1, VCAM-1, FVIII, and E-selectin were associated with incident CKD and ≥30% eGFR decline in a large cohort study. Higher FVIII was also associated with incident albuminuria.
引用
- Short SAP, Wilkinson K, Long DL, et al. Endothelial Dysfunction Biomarkers and CKD Incidence in the REGARDS Cohort. Kidney Int Rep. 2024. PMID: 39081743. doi:10.1016/j.ekir.2024.04.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。